Abstract
Despite advances in the development of anti-hyperglycaemic drugs and a greater focus on cardiovascular risk modification for patients with diabetes, cardiovascular disease remains the most common complication of type 2 diabetes. Since their initial availability in 1997, the thiazolidinediones have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the thiazolidinediones have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for cardiovascular disease, and hold promise with regard to modification of cardiovascular risk. In a recently reported large-scale clinical trial, pioglitazone was associated with improved cardiovascular outcomes in patients with type 2 diabetes and prevalent atherosclerotic disease. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the thiazolidinediones on cardiovascular risk factors and clinical outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 65-71 |
| Number of pages | 7 |
| Journal | Diabetes and Vascular Disease Research |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| State | Published - Sep 1 2006 |
Keywords
- Atherosclerosis
- Inflammation
- Peroxisome proliferator-activated receptor
- Pioglitazone
- Rosiglitazone
- Thiazolidinedione
- Troglitazone
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine